Oncolytics Biotech Inc T.ONC

In today's world the paths to FDA Approval are many

[Noteable]

May 31, 2023 - the FDA has granted a path forward for vadadustat in anemia associated with chronic kidney disease in dialysis-dependent patients, which will not require the company to submit new data, despite its March 2022 rejection of the drug because of safety concerns.. 

https://www.biospace.com/article/akebia-to-resubmit-anemia-drug-application-to-fda-after-initial-rejection/

[Noteable]

The FDA's paths to oncology drug approval have been opened by the Congressional probe 2 months ago.  In March, the FDA’s actions in preventing and responding to the shortages were probed in Congress as the House Committee on Energy and Commerce launched an investigation to uncover if the agency is “effectively using its existing authorities.” Consequently, in response to this

[Noteable]

... and in oncology, the many paths to FDA approval are not determined by CRs, athough this is the ultimate, long-term goal.

[Lesalpes29]

Thank you for the work you do here. More than 700 posts in 5 months only for Onc is a lot of work. GL

[Noteable]

700 posts on ONCY in 5 months on this message board just illustrates the "brilliant" opportunities that pelareorep presents.

[Noteable]

Should read: "...just illustrates the "brilliant" opportunities that pelareorep represents."

[Buckhenry]

The dreamers  sure get their  tail feathers  ruffled when anyone disagrees with their narrative. Reminds of the liberal democrats that's burned downtown Portland a few years ago cause they didn't get their way 

[Azzak34]

Ooh tell me more! Wait, are you an orange guy fan? Hang on a minute, is this you? My old pal? 

[Noteable]

Here's a recent example --- June 05, 2023, The FDA has signed off on an amended trial protocol for Theratechnologies’ solid tumors medicine, lifting its clinical hold and setting the Canadian biotech free to proceed.     The phase 1 study for TH1902, also known as sudocetaxel zendusortide, has been on pause since December 2022, when Theratechnologies got a glimpse

[Noteable]

Clinical trials in oncology have terminology, including primary endpoints and surrogate endpoints, which are results that are measured at certain points during a study and/or at the completion of a study to see if a given medication has worked (e.g., did the drug demonstrate a significant improvement versus the comparative treatment?) and its safety (e.g., what are the possible side